



ELN Frontiers Meeting 2012

MYELOID NEOPLASMS: APPROACHING CURE

9-11 November 2012
Swissôtel The Bosphorus
Istanbul, Turkey

Chairs:

Michele Bacarani, MD
Rüdiger Hehlmann, MD, PhD

Co-Chairs:

Francisco Cervantes, MD, PhD
Gert J. Ossenkoppele, MD, PhD
Theo de Witte, MD, PhD





Welcome

Dear colleague,

We are delighted to invite you to the ELN Frontiers Meeting 2012 entitled 'Myeloid Neoplasms: Approaching Cure'. This official meeting of the European LeukemiaNET (ELN) is taking place on November 9-11 at the Swissôtel The Bosphorus in Istanbul, Turkey. The meeting is co-sponsored by the University of Heidelberg and the Turkish Society of Haematology, and it is endorsed by EUTOS for CML.

The ELN Frontiers meeting is dedicated to provide an opportunity to facilitate discussions with renowned experts in haematology from all across Europe and to share new developments in the field of myeloid neoplasms. Recognising important recent advances in the diagnosis and targeted treatment, ELN Frontiers 2012 will focus on chronic myeloid leukaemia (CML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). The curriculum will discuss major treatment advances, molecular and diagnostic tools, clinical management issues and promising clinical research in these disease areas.

In the past two decades, we have witnessed dramatic advances in the management of myeloid neoplasms. Second generation tyrosine kinase inhibitors are now proven to achieve fast, deep and sustained responses in first-line treatment of CML patients. Thus, clinical response milestones in CML are expected to evolve once again. The recent availability of Janus kinase inhibitors for the treatment of MPNs has already led to significant quality of life improvements for patients. New breakthroughs in our understanding of the molecular pathogenesis of MDS and AML will impact the future management of these diseases.

In 2012, a greater emphasis will be placed on the poster sessions to recognise and disseminate the contributions of researchers in this field. Accepted poster abstracts will be shared in our special edition of the ELN Newsletter and as many as 30 will be selected for oral presentation. We encourage you to share your research.

The ELN Frontiers meeting builds upon 6 years of education innovation in myeloid malignancies. Please join us for an exciting congress with a rich mix of plenary and interactive parallel sessions including meet-the-experts, clinical case discussions, debates, poster walks and oral presentations.

Yours sincerely,

Michele Baccarani and Rüdiger Hehlmann

Saturday, 10 November 2012

- 08.15** Opening remarks and introduction
08.25 Welcome address from the Turkish Society of Hematology

Session 1: Epidemiology and aetiology

- 08.35** Chronic myeloid leukaemia (CML)
08.50 Chronic myeloproliferative neoplasms (MPN)
09.05 Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS)
09.20 Panel discussion: Commonalities and differences in aetiology and molecular pathogenesis of myeloid neoplasms

Session 2: Major advances in therapy

- 09.45** CML: A success of targeted therapy
10.00 MPN: The results of targeted therapy
10.15 AML: Cytotoxic treatment, is more really better?
10.30 MDS: From support to interventional therapy
10.45 Questions & answers
11.00 **Poster walk & refreshment break**
Move to parallel sessions

Session 3: Major advances in diagnosis and monitoring

| | 3a: CML | 3b: MPN | 3c: AML and MDS |
|--------------|---|---|--|
| 11.30 | Progress in cytogenetics | Molecular heterogeneity | The value of cytogenetics |
| 11.45 | Progress in molecular testing | Pre-fibrotic primary myelofibrosis: Pros and cons – a debate | Molecular diagnosis |
| 12.00 | Progress in genome analysis | | Monitoring iron overload |
| 12.15 | Questions & answers | Questions & answers | The value of flow cytometry in diagnosis and therapy evaluation in MDS |
| 12.30 | Questions & answers | Questions & answers | Questions & answers |
| 12.45 | Poster walk & refreshment break Move to plenary hall | | |

13.00

Lunch

Reconvene in parallel sessions

Session 4: Selected oral poster presentations

4a

4b

4c

4d

14.00

Chronic myeloid
leukaemia

Myeloproliferative
neoplasms

Acute myeloid
leukaemia

Myelodysplastic
disorders

15.00

Poster walk & refreshment break

Move to plenary hall

Session 5: Targeting leukaemia: Future developments

15.30

CML: Modelling treatment on patient and disease characteristics

15.45

MPN: Early or late intervention?

16.00

AML: Different diseases require different treatments

16.15

MDS: Focus on haematopoietic growth factors: EPO, G-CSF and TPO

16.30

Questions & answers

17.00

Poster walk

Agenda

Sunday, 11 November 2012

Meet the experts (parallel sessions)

08.30

Chronic myeloid leukaemia I

Chronic myeloid leukaemia II

MPN: Myelofibrosis

MPN: Polycythaemia vera and essential thrombocythaemia

Acute myeloid leukaemia

Myelodysplastic syndrome

09.30

Move to session 6

Session 6: Major advances in diagnosis and monitoring

6a: CML

6b: AML and MDS

6c: MPN

09.45

Which side effects of TKI therapy are most important?

The importance of minimal residual disease

Prognosis, baseline and dynamics

10.00

Are there effects of TKI on the immune system?

Infectious complications

10.05 Clinically important endpoints

10.15

Do adverse events herald organ toxicity? Focus on heart, liver and pancreas

Transfusion and iron chelation policies

10.25 Case presentation

10.30

Questions & answers

Questions & answers

10.45

Case presentation

Case presentation

10.40 Questions & answers

11.00

Poster walk & refreshment break

Move to plenary hall

Session 7: The path to cure

- 11.30** CML: Second generation TKI alone vs. other options?
- 11.45** MPN: From palliation to long term disease control and cure
- 12.00** AML: Focus on immune control and targeted therapy
- 12.15** MDS: Is allogeneic stem cell transplantation the only curative approach or can alternative approaches cure some patients as well?
- 12.30** Round table discussion
- 13.00** **Lunch**

Faculty

Sergio Amadori, MD

Tor Vergata University Hospital
Rome, Italy

Michele Baccarani, MD

University of Bologna
Bologna, Italy

Tiziano Barbui, MD

Ospedali Riunitim
Bergamo, Italy

Giovanni Barosi, MD

IRCCS Policlinico San Matteo
Pavia, Italy

Carlos Besses, MD, PhD

Hospital del Mar
Barcelona, Spain

Francisco Cervantes, MD, PhD

Hospital Clinic Barcelona
Barcelona, Spain

Hartmut Döhner, MD

Klinik für Innere Medizin III
Zentrum für Innere Medizin
Universitätsklinikum Ulm
Ulm, Germany

**Francis J. Giles, MB, MD, FRCPI,
FRCPath**

National University of Ireland
Galway, Ireland

John M. Goldman, DM, FRCP, FRCPath

Imperial College London
London, United Kingdom

Anthony R. Green, PhD, FRCP, FRCPath

Cambridge Institute for Medical Research
Addenbrooke's Hospital
Cambridge, United Kingdom

David Grimwade, PhD

King's College London School of Medicine
London, United Kingdom

François Guilhot, MD

CHU de Poitiers
Poitiers, France

Gabriele Gugliotta, MD

University of Bologna
Bologna, Italy

Detlef Haase, MD, PhD

Georg-August-Universität Göttingen
Göttingen, Germany

Claudia Haferlach, MD

MLL Munich Leukemia Laboratory
Munich, Germany

Ibrahim C. Haznedaroglu, MD

Hacettepe University Medical School
Ankara, Turkey

Rüdiger Hehlmann, MD, PhD

University of Heidelberg
Mannheim, Germany

Jerzy Holowiecki, MD, PhD

Maria Skłodowska-Curie Memorial Cancer
Centre and Institute of Oncology
Gliwice, Poland

Joop H. Jansen, PhD

Radboud University Nijmegen
Medical Center
Nijmegen, The Netherlands

Laurent Knoops, MD, PhD

Université catholique de Louvain
Brussels, Belgium

Arjan A. van de Loosdrecht, MD, PhD,

VU University Medical Center
Amsterdam, The Netherlands

Michael Lübbert, MD, PhD

University of Freiburg
Freiburg, Germany

François-Xavier Mahon, MD, PhD

CHU Pellegrin
Bordeaux, France

Martin C. Müller, MD

University of Heidelberg
Mannheim, Germany

Daniel Nowak, MD

University of Heidelberg
Mannheim, Germany

Gert J. Ossenkoppele, MD, PhD

VU University Medical Center
Amsterdam, The Netherlands

Oliver G. Ottmann, MD, PhD

Johann Wolfgang Goethe University
Frankfurt, Germany

Francesca Palandri, MD

University of Bologna
Bologna, Italy

Fabrizio Pane, MD

University of Naples Federico II
Naples, Italy

Uwe Platzbecker, MD, PhD

Universitätsklinikum Carl Gustav Carus
Dresden, Germany

Kimmo Porkka, MD, PhD

Helsinki University Central Hospital
Helsinki, Finland

John Porter, MD

University College London
London, United Kingdom

Andreas Reiter, MD

University of Heidelberg
Mannheim, Germany

Gianantonio Rosti, MD

University of Bologna
Bologna, Italy

Tomasz Sacha, MD

Jagiellonian University
Krakow, Poland

Giuseppe Saglio, MD

University of Turin
Orbassano-Torino, Italy

Valeria Santini, MD

Azienda Ospedaliera Universitaria Careggi
Florence, Italy

Miguel A. Sanz, MD, PhD

University Hospital La Fe
Valencia, Spain

Susanne Saussele, MD

University of Heidelberg
Mannheim, Germany

Richard Schlenk, MD

University Hospital of Ulm
Ulm, Germany

Teoman Soysal, MD

Istanbul University
Istanbul, Turkey

Juan Luis Steegmann, MD, PhD

Hospital Universitario de la Princesa
Madrid, Spain

Simona Soverini, PhD

University of Bologna
Bologna, Italy

Alessandro M. Vannucchi, MD

University of Florence
Florence, Italy

Pierluigi Viale, MD

Clinica di Malattie Infettive
University of Bologna
Bologna, Italy

Theo J. M. de Witte, MD, PhD

Radboud University Nijmegen
Medical Center
Nijmegen, The Netherlands

CME

Target audience:

The programme is designed for haematologists, oncologists and other healthcare professionals who are involved in the treatment of patients with myeloid malignancies: Chronic Myeloid Leukaemia (CML), Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)

Programme goal:

The programme goal is to provide a state-of-the-art update on current developments in the diagnosis, treatment and management of CML, AML, MDS and MPN and to discuss open issues in research and clinical practice.

Learning objectives:

At the end of the meeting, participants will be able to:

- Analyse currently available options for first-line CML therapy, taking into account the safety and efficacy profiles of various therapeutic agents
- Distinguish between CML (Ph-positive) and Ph-negative myeloproliferative neoplasms and how these affect treatment decisions
- Better understand the biology of MPN, the pathways involved, and the role of JAK2 mutations in disease aetiology
- Discuss advances in the diagnosis and current prognostic models for CML, AML, MDS and MPN
- Critically review clinical evidence and current therapeutic algorithms, including the ELN recommendations, to make appropriate treatment decisions in myeloid malignancies
- Explain the molecular pathogenesis of myeloid malignancies and discuss novel treatment approaches

Statements

CPD / CME accreditation:

An application for CPD / CME accreditation of this educational programme has been submitted to the Federation of the Royal Colleges of Physicians of the United Kingdom and the Turkish Association of Medicine.

Financial relationships and off-label / investigational uses of drugs:

The relevant financial relationships of those persons in a position to control the content of this activity will be disclosed prior to the start of the educational activity. Participants are advised that this activity will contain references to unlabeled / unapproved / investigational uses of drugs.



This activity is an official meeting of the ELN



Co-sponsored by:



Turkish Society
of Haematology



University
of Heidelberg

Endorsed by EUTOS for CML

EUTOS for CML



Supported by an unrestricted educational grant from Novartis



Scientific Programme Coordinator

